) recently announced positive results from the
multiple-ascending-dose (MAD) section of the company's phase I
study on OMS824. We note that OMS824 is the lead compound in
Omeros' phosphodiesterase 10 (PDE10) program.
Omeros is developing the candidate as a PDE10 inhibitor, which
is an enzyme expressed in areas of the brain linked to a wide
range of diseases, including Huntington's disease and
schizophrenia, that affect cognition.
Omeros enrolled 64 healthy male volunteers for the study.
Results from the study showed that OMS824 was well tolerated by
all the volunteers. Moreover, the candidate effectively inhibited
PDE10, which support continuing development for the treatment of
Huntington's disease, schizophrenia and other central nervous
system disorders. The only drug-related adverse event noticed
during the study was mild somnolence that too at the highest
In Dec 2012, Omeros reported promising data from the
single-ascending-dose (SAD) study portion of a phase I study on
OMS824. Based on the positive data published by the company on
OMS824 in Dec 2012 and Mar 2013, it now plans to advance the
candidate into phase II development.
We note that currently companies like
) have drugs for the treatment of schizophrenia and Huntington's
Another interesting candidate at Omeros is OMS302, which is
under phase III development for intreating patients undergoing
intraocular lens replacement surgery. Omeros plans to submit a
New Drug Application (NDA) for the candidate in the US soon. The
company also has plans to submit a Marketing Authorization
Application for OMS302 to the European Medicines Agency in
mid-2013. The pipeline at Omeros also includes OMS103HP (for
patients undergoing arthroscopic partial meniscectomy surgery).
The candidate is in phase III development.
Omeros, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). Other biopharma stocks such as
) currently look more attractive carrying a Zacks Rank #1 (Strong
CYTOKINETCS INC (CYTK): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
OMEROS CORP (OMER): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.